ClinicalTrials.gg
CompletedNCT06115993Updated May 7, 2026

A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients

A Phase 1/2 interventional study of AHB-137 injection and Placebo in Hepatitis B, Chronic, sponsored by Ausper Biopharma Co., Ltd.. Completed at 3 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Ausper Biopharma Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic — 6 open to participants now, 8 under way, 1 of them phase 3. Hepatitis B Virus Antisense Oligonucleotide AHB-137 · Hepatitis B, Chronic.

Enrollment
5th of 11
129 · median 86
Started
2023
with 1 other
Phase 1/2
Only one
of the 11
Registered
2nd of 11
by date
Lead sponsor
8 of 11
Ausper Biopharma Co., Ltd.

Among the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, this one is the 5th largest by enrollment, is one of 2 that started in 2023, is the only one in phase 1/2, and was the 2nd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

6 of the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About Hepatitis B Virus Antisense Oligonucleotide AHB-137

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy participants after single and multiple doses, and evaluate the preliminary efficacy of AHB-137 in CHB participants after up to 24 weeks of treatment as a proof-of-concept.

Read the detailed description

This study is a three-part study of AHB-137, including Part Ia, Part Ib and Part IIa. Part Ia evaluates the safety, tolerability, pharmacokinetics of AHB-137 following single-ascending doses (SAD) and multiple-ascending doses (MAD) in healthy participants. Part Ib is a multiple-dose study to assess the safety, tolerability, pharmacokinetics, and initial efficacy of AHB-137 in CHB participants following weekly dosing for 4 weeks with two loading doses in the first two weeks. Part IIa is a multiple-dose study to evaluate the preliminary efficacy, safety and pharmacokinetics of AHB-137 in CHB participants following weekly dosing for 24 weeks with two loading doses in the first two weeks.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants are required to meet all the following inclusion criteria in order to be enrolled in the study (Part Ia):

    1. The participants voluntarily participate in the study, and sign the Form (ICF) prior to screening;
    2. The participants are able to comply with all the protocol requirements;
    3. The participants (and partners) are willing to take effective measures from the screening until at least 6 months after the last dosing;
    4. Male or female aged 18-55 when signing ICF;
    5. (BMI) between 18 to 28 kg/m2 (inclusive) and body weight equal to or over 50 kg for male and 45 kg for female;
    6. Vital signs and physical examination are normal, or abnormal values are not .
  • CHB participants are required to meet all the following inclusion criteria in order to be enrolled in the study (Part Ib and part IIa):

    1. The participants voluntarily participate in the study, and sign the Informed Consent Form (ICF) prior to screening;
    2. The participants are able to comply with all the protocol requirements;
    3. The participants (and partners) are willing to take effective contraceptive measures from the screening until at least 6 months after the last dosing;
    4. Male or female aged 18-65 when signing ICF;
    5. Body Mass Index (BMI) between 18 to 32 kg/m2 (inclusive) and body weight equal to or over 45 kg for male and 40 kg for female;
    6. participants who have documented chronic infection equal to or above 6 months prior to screening.
    7. Stable treatment of HBeAg negative CHB participants;
    8. Currently receiving single-agent treatment with stable NAs (TDF, TAF, or ETV) for at least 6 months and no changes in the NAs treatment regimen are planned during the trial;
    9. Serum ≤2×, HBV DNA \< 100 IU/mL. Dose increasing stage of Ib: 100 IU/mL \<HBsAg≤1000 IU/mL; Dose expansion stage of Ib: 1000 IU/ml \< HBsAg≤3000 IU/mL at screening; IIa phase: 100 IU/ml \< HBsAg≤ 3000 IU/mL at screening;
    10. Participants who are willing and able to terminate NA treatment according to the protocol in IIa stage.

Exclusion criteria

Exclusion Criteria:

  • Healthy participants are required to not meet any of the exclusion criteria in order to be enrolled in the study (Part Ia):

    1. Any suspicat screening ion of drug component allergy, or allergic constitution (various drug and food allergy, and judged by the investigator to be ) in participants;
    2. Blood donation or blood loss not less than 400 mL within 12 weeks before screening;
    3. Drug administration that change the activity of liver enzymes within 28 days prior to screening;
    4. Receipt of another drug or device within 3 months before first dosing (interventional treatment);
    5. Clinically significant (ECG) abnormalities on screening ECG;
    6. TdP high-risk factors (hypokalemia, hypomagnesemia, decompensated heart failure and acute myocardial infarction), and above 450 msec in participants (judged by investigator based on actual screening conditions);
    7. Pregnant (positive pregnancy test), recently ready to conceive, or lactating female;
    8. Clinically significant lab examination abnormalities, or other clinically significant diseases discovered within 12 months before screening, including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrinological, tumor, pulmonary, immune, mental, or cardiovascular and cerebrovascular diseases;
    9. Any acute disease or concomitant medication occurred during screening to the first dosing;
    10. Alcohol consumption, or positive alcohol test 24 hours before drug dosing;
    11. Positive test for urinalysis (including Morphine, Cannabis) in participants;
    12. Other factors resulting in participant becoming unsuitable for the study, determined by the investigator.
  • CHB participants are required to not meet any of the exclusion criteria in order to be enrolled in the study (Part Ib and Part IIa):

    1. Any suspicion of drug component allergy, or allergic constitution (various drug and food allergy, and judged by the investigator to be clinically significant) in participants;
    2. Blood donation or blood loss more than 400 mL within 12 weeks before screening; Blood transfusion; Blood donation or blood loss not less than 200 mL within 1 month before screening;
    3. Any oligonucleotide or siRNA treatments within 12 months before first dosing;
    4. Any , immunomodulator (e.g. Thymosin) or cytotoxic drug administrations within 6 months before first dosing; Vaccination within 1 month in prior of screening, or plan to take any vaccines during the study;
    5. Receiving anticoagulant therapy for Ib phase (e.g., Warfarin, Factor Xa Inhibitors or antiplatelet drugs such as Clopidogrel);
    6. Any clinically significant liver diseases, including but not limited to hepatitis caused by other pathogenic infections, hemochromatosis, Wilson disease, primary biliary cirrhosis, liver diseases, alcoholic liver disease, severe non-alcoholic fatty liver disease, Drug-induced liver injury, etc.;
    7. Personal history of cirrhosis or progressive hepatic fibrosis (e.g., the participant undergoes hepatic histopathological examination, which indicates cirrhosis, or undergoes endoscopic examination indicating esophagogastric varices);
    8. Confirmation or suspicion of decompensated cirrhosis, including but not limited to hepatic encephalopathy, hepatorenal syndrome, esophageal and gastric variceal bleeding, ascites, primary hepatocellular carcinoma, etc.;
    9. History of within the past 5 years, except for certain tumors that can be cured by surgical resection (e.g., non-melanoma skin cancer, cervical intraepithelial neoplasia, thyroid neoplasm, breast tumor, etc. that have been treated without signs of recurrence);
    10. Combined sever diseases of circulation, digestion, respiration, urinary, blood, metabolism, immune, nervous system, etc.;
    11. Participants for IIa phase with high-risk factors for TdP (hypokalemia, hypomagnesemia, decompensated heart failure, and acute myocardial infarction), baseline QTc interval longer than 450 ms (determined by the researchers based on actual screening);
    12. Acute infection within 2 weeks prior to screening;
    13. Receipt of another investigational drug or device within 1 month before screening (interventional treatment);
    14. Laboratorial examination: blood counts\<90 x 10\^9/L, \<1.3 x 10\^9/L, \<90 g/L, serum total ≥2 x , albumin\<30 g/L, rate (calculated by formula) ≤60 mL/min, >1.5;
    15. Alpha-fetoprotein (AFP) >70 ug/L, or imaging suspicion of malignant hepatic space-occupying;
    16. antibody/HCcAg positive, AIDS antigen/antibody positive, or Treponema Pallidum antibody positive and Rapid Plasma Reagin (RPR) or Toluidine Red Unheated Serum Test (TRUST) positive, or Hepatitis D antibody positive;
    17. LSM≥12.4 kPa when screening;
    18. Pregnant (positive pregnancy test) or lactating female;
    19. Positive test for urinalysis (including Morphine, Cannabis) or alcohol test in participants;
    20. Other factors results in unsuitable for the study, determined by the investigator.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Part Ia: dosing in healthy participants

    SAD of 75 mg, 150 mg, 300 mg and 450 mg AHB-137 and MAD of 150 mg and 300 mg AHB-137 by subcutaneous injections within a month in healthy participants.

    Drug: AHB-137 injection · Drug: Placebo

  • Experimental
    Part Ib: dosing in CHB participants

    Dose escalation cohort: MAD of 150 mg and 300 mg AHB-137 by subcutaneous injections within a month in CHB participants who are under stable NAs therapy. Dose expansion cohort: Multiple doses of 300 mg AHB-137 by subcutaneous injections within a month in CHB participants who are under stable NAs therapy.

    Drug: AHB-137 injection · Drug: Placebo

  • Experimental
    Part IIa: proof of concept

    Multiple doses of 225 mg or 300 mg AHB-137 by subcutaneous injections within 24 weeks in CHB participants who are under stable NAs therapy.

    Drug: AHB-137 injection

Interventions

  • AHB-137 injection will be administered subcutaneously.

  • DrugPlacebo

    Placebo will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Number of healthy participants with TEAEs, SAEs

    Time frame: Up to 30 days for SAD; up to 113 days for MAD

  2. Number of healthy participants with clinically significant changes in laboratory parameters

    Time frame: Up to 30 days for SAD; up to 113 days for MAD

  3. Number of healthy participants with clinically significant changes in vital signs

    Time frame: Up to 30 days for SAD; up to 113 days for MAD

  4. Number of healthy participants with clinically significant changes in ECG

    Time frame: Up to 30 days for SAD; up to 113 days for MAD

  5. Number of healthy participants with ADA

    Time frame: Up to 30 days for SAD; up to 113 days for MAD

  6. The pharmacokinetic profile of AHB-137 in healthy participants: the Cmax of AHB-137

    Time frame: Up to 30 days for SAD; up to 113 days for MAD

  7. The pharmacokinetic profile of AHB-137 in healthy participants: Tmax of AHB-137

    Time frame: Up to 30 days for SAD; up to 113 days for MAD

  8. The pharmacokinetic profile of AHB-137 in healthy participants: AUC of AHB-137

    Time frame: Up to 30 days for SAD; up to 113 days for MAD

  9. The pharmacokinetic profile of AHB-137 in healthy participants: t1/2 of AHB-137

    Time frame: Up to 30 days for SAD; up to 113 days for MAD

  10. Number of CHB participants with TEAEs, SAEs

    Time frame: Up to 113 days for Ib

  11. Number of CHB participants with clinically significant changes in laboratory parameters

    Time frame: Up to 113 days for Ib

  12. Number of CHB participants with clinically significant changes in vital signs

    Time frame: Up to 113 days for Ib

  13. Number of CHB participants with clinically significant changes in ECG

    Time frame: Up to 113 days for Ib

  14. Proportion of participants achieving HBsAg lower than LLOQ (0.05 IU/mL) and HBV DNA lower than LLOQ at the end of treatment with AHB-137, regardless of whether HBsAg seroconversion is observed

    Time frame: At week 24 for IIa

Secondary outcomes

  1. The anti-HBV efficacy of AHB-137 in CHB participants: evaluate the serum levels of HBV DNA, HBsAg, HBV RNA, HBsAb, HBeAb

    Time frame: Up to 113 days for Ib; Up to 72 weeks for IIa

  2. Evaluate the serum levels of sensitive HBsAg (LLOQ ≤0.005 IU/mL) and HBcrAg.

    Time frame: Up to 72 weeks for IIa

  3. The pharmacokinetic profile of AHB-137 in CHB participants: the Cmax of AHB-137

    Time frame: up to 113 days for Ib; Up to 48 weeks for IIa

  4. The pharmacokinetic profile of AHB-137 in CHB participants: Tmax of AHB-137

    Time frame: up to 113 days for Ib; Up to 48 weeks for IIa

  5. The pharmacokinetic profile of AHB-137 in CHB participants: AUC of AHB-137

    Time frame: up to 113 days for Ib; Up to 48 weeks for IIa

  6. The pharmacokinetic profile of AHB-137 in CHB participants: t1/2 of AHB-137

    Time frame: up to 113 days for Ib; Up to 48 weeks for IIa

  7. Number of CHB participants with ADA

    Time frame: Up to113 days for Ib; Up to 48 weeks for IIa

  8. Number of CHB participants with TEAEs, SAEs

    Time frame: Up to 72 weeks for IIa

  9. Number of CHB participants with clinically significant changes in laboratory parameters, ECG, and vital signs

    Time frame: Up to 72 weeks for IIa

  10. Proportion of CHB participants achieving HBsAg lower than LLOQ and HBV DNA lower than LLOQ during or after 24-week treatment, regardless of whether HBsAg seroconversion is observed

    Time frame: Up to 72 weeks for IIa

  11. Proportion of CHB participants meeting the discontinuation criteria for NA treatment

    Time frame: At 48 weeks for IIa

  12. Sequencing of the Viral DNA and/or viral RNA analysis for detection of drug resistance in the target region of AHB-137

    Time frame: Up to 113 days for Ib; Up to 72 weeks for IIa

07

Study locations

3 sites
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, China
  • Nanfang Hospital, Southern Medical University
    Guangzhou, China
  • The First Hospital of Jilin University
    Jilin City, China
08

References and documents

Publications

  • Wang W, Mai J, Hou J, Xu Z, Yu X, Ren H, Liang X, Yang Y, Liu Z, Zhang H, Zhong S, Wen Y, Lu T, Cao H, Qiu X, Wang L, Zhao D, Wang M, Yang C, Cheng G, Niu J, Ding Y. Safety, pharmacokinetics and antiviral activity of AHB-137 in healthy volunteers and chronic hepatitis B patients: a phase 1a/1b study. Hepatol Int. 2026 May 23. doi: 10.1007/s12072-026-11102-7. Online ahead of print. PubMed 42176239 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Dec 2024, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2023
First posted
Nov 3, 2023
StartActual
Aug 3, 2023
Primary completionActual
Dec 3, 2024
CompletionActual
Nov 10, 2025
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06115993
Responsible party
Sponsor
First posted
Nov 3, 2023
Start date
Aug 3, 2023
Primary completion
Dec 3, 2024
Completion
Nov 10, 2025
Last update
May 7, 2026

Study contacts

Yanhua Ding
principal investigator · The First Hospital of Jilin University
Junqi Niu
principal investigator · The First Hospital of Jilin University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hepatitis B Virus Antisense Oligonucleotide AHB-137

Start the discussion